The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women
- 31 August 2005
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 41 (12), 1678-1689
- https://doi.org/10.1016/j.ejca.2004.10.020
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Aromatase inhibitors: mechanism of action and role in the treatment of breast cancerSeminars in Oncology, 2003
- Influence of Letrozole and Anastrozole on Total Body Aromatization and Plasma Estrogen Levels in Postmenopausal Breast Cancer Patients Evaluated in a Randomized, Cross-Over StudyJournal of Clinical Oncology, 2002
- Estrogen and the Risk of Breast CancerNew England Journal of Medicine, 2001
- Use of aromatase inhibitors in breast carcinoma.Endocrine-Related Cancer, 1999
- Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinomaCancer, 1998
- Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancerAnnals of Oncology, 1998
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.Journal of Clinical Oncology, 1998
- The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancerBritish Journal of Cancer, 1990
- A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive TumorsNew England Journal of Medicine, 1989